ftInvstr
GUFICBIO · Healthcare ₹446.0 +1.72% Mkt Cap ₹4457 Cr overvalued

GUFICBIO

Healthcare Drug Manufacturers - Specialty & Generic
₹446.0
+1.72% today · 30d +11.47%
as of 2026-09-04
Price · Daily Candles
AI narrative is temporarily unavailable for GUFICBIO. The deterministic sections below render from live data.
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹261 Cr
+16.58% YoY
NET PROFIT
₹22 Cr
+70.71% YoY
OPM
18.01%
+2.78pp YoY
EPS
₹2.22
PE 61.04
Intrinsic value · DCF ₹91.32 · Margin of safety -79.5% (overvalued) · FCF yield 0.31%
◇ Sector Position
PEERPEROCE %
GUFICBIO61.0413.0
SUNPHARMA37.5721.44
DIVISLAB89.1821.56
ZYDUSLIFE24.6424.22
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
66
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 90
Valuation STRETCHED 20
Growth STEADY 55
Profitability DECENT 68
Technicals STRONG 70
Risk LOW 90
Key Stats
TTM PE
61.04
P/B
6.76
52W HIGH
₹453.95
OFF HIGH
-1.75%
DIV YIELD
0.02%
MKT CAP
₹4457 Cr
◉ Active Signals
MACDBullish1.5135
RSI(14)Bullish66.72
Near 52W HighBullish-1.75
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold GUFICBIO and at what entry.

Sign up freeSign in